Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Also known as well-differentiated thymic carcinoma, atypical thymoma, or epithelial thymoma, this type of thymoma displays morphologic characteristics of a well-differentiated carcinoma. The majority of cases occur in the anterior mediastinum as Masaoka stage II or stage III tumors. It is almost always invasive, it recurs frequently, and metastasizes in approximately 20% of the cases.
Biomarker and diagnostic research for thymoma type B3 has been reported in the published literature.
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
12 publications have been identified in PubMed for thymoma type B3. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (25%), and Diagnostic / Biomarker (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 50% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:11 PM UTC
Research summaries |
3 |
25% |
Testing and diagnosis research | 2 | 17% |
Disease patterns and progression | 1 | 8% |
Suzuki M (2026). [PMID: 41982610](https://pubmed.ncbi.nlm.nih.gov/41982610/). *Mediastinum*. [Review / Meta-Analysis]
Lee IH (2026). [PMID: 41682639](https://pubmed.ncbi.nlm.nih.gov/41682639/). *Journal of clinical medicine*. [Case Report / Case Series]
Bille A (2025). [PMID: 41098392](https://pubmed.ncbi.nlm.nih.gov/41098392/). *Mediastinum (Hong Kong, China)*. [Case Report / Case Series]
Weissferdt A (2025). [PMID: 39150796](https://pubmed.ncbi.nlm.nih.gov/39150796/). *International journal of surgical pathology*. [Case Report / Case Series]
Yamada Y (2025). [PMID: 41098390](https://pubmed.ncbi.nlm.nih.gov/41098390/). *Mediastinum (Hong Kong, China)*. [Review / Meta-Analysis]
Kamada Y (2025). [PMID: 41253321](https://pubmed.ncbi.nlm.nih.gov/41253321/). *Kyobu geka. The Japanese journal of thoracic surgery*. [Case Report / Case Series]
Palić J (2025). [PMID: 40488328](https://pubmed.ncbi.nlm.nih.gov/40488328/). *Veterinary clinical pathology*. [Case Report / Case Series]
Suster DI (2025). [PMID: 40666531](https://pubmed.ncbi.nlm.nih.gov/40666531/). *Mediastinum (Hong Kong, China)*. [Review / Meta-Analysis]
Poma AM (2025). [PMID: 41954343](https://pubmed.ncbi.nlm.nih.gov/41954343/). *Pathologica*. [Diagnostic / Biomarker]
Weissferdt A (2024). [PMID: 37696593](https://pubmed.ncbi.nlm.nih.gov/37696593/). *Journal of clinical pathology*. [Diagnostic / Biomarker]
AI-curated news mentioning thymoma type B3
Updated Aug 26, 2026
Recent research highlights a link between thymoma-related autoimmunity and cases of fulminant myocarditis leading to sudden death. This study underscores the need for increased awareness and monitoring of cardiac complications in patients with thymoma.
A recent study highlights an unexpected decline in pulmonary function in a patient with thymoma, which was initially misdiagnosed as obstructive bronchiolitis. This case underscores the need for careful evaluation of pulmonary symptoms in patients with thymoma.
A nationwide analysis in Japan from 2018 to 2022 reveals treatment practices for advanced thymoma and advanced thymic carcinoma. This study provides insights into evolving therapeutic approaches for these rare tumors.